AstraZeneca Pharma India Limited's promoter, AstraZeneca Pharmaceuticals AB, Sweden, has submitted a declaration to stock exchanges under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The disclosure was filed with both BSE Limited and the National Stock Exchange of India Limited, where shares of AstraZeneca Pharma India Limited are listed under the symbol ASTRAZEN.
The declaration confirms that AstraZeneca Pharmaceuticals AB did not create any encumbrance on its promoter-held shares in AstraZeneca Pharma India Limited during the financial year ended March 31, 2026. Encumbrance under the regulations includes pledges, liens, and any other forms of charges against shares.
AstraZeneca Pharmaceuticals AB further stated that the shares it holds as promoter of AstraZeneca Pharma India Limited are not subject to any encumbrance. The promoter's entire holding in the Indian listed entity remains free of any restrictive claims or charges.
The disclosure was signed by Lars-Johan Cederbrant, Director and Authorised Signatory of AstraZeneca Pharmaceuticals AB. The declaration was dated April 2, 2026. AstraZeneca Pharma India Limited submitted the filing to the exchanges on June 9, 2026 after market hours.
The Regulation 31(4) filing is an annual disclosure requirement under the SEBI Takeover Code. Promoters of listed entities must submit this declaration each financial year regarding the encumbrance status of their shareholding. AstraZeneca Pharmaceuticals AB holds its promoter stake in AstraZeneca Pharma India Limited directly and without any pledge or charge.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.